Oskar from Norway

Registered at the short selling broker Skilling, 5 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

GlaxoSmithKline Plc (GSK) shares information

GlaxoSmithKline Plc

24h Change

-1.15 %


Live rate: Market closed

Stock data per Thursday 13 Aug, 2020

New York Stock Exchange
-0.47858 (-1.15%)
US Market is closed

Live Stock price in graph for GlaxoSmithKline Plc (GSK)

  • Latest Volume

    2,853,320 (-13.92 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change


Quick links

Broker recommendations for GlaxoSmithKline Plc

The GlaxoSmithKline Plc stock is rated at 1.666667 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Tuesday 11 August, 2020 by a total of 21 brokers. This means that the consensus of the 21 different brokers is leaning toward to moderate buy/hold.

2 (9.52%)
0 (0%)
9 (42.86%)
2 (9.52%)
8 (38.1%)

Price target by analysts

The 17 latest analyst estimates, per Wednesday 12 August, 2020, show the following high, low and average price targets.
Target Average: 48.2 USD
Target High: 57.04 USD
Target Low: 38.62 USD


Latest news about GlaxoSmithKline Plc

Below you can find the most recent news posts about GlaxoSmithKline Plc, primarily from US and UK based news sources.

EU to Buy 200 Million Doses of the Potential COVID-19 Vaccine From Johnson & Johnson

Friday, 14 August 2020, 00:33:45
The European Commission has concluded exploratory talks with Johnson & Johnson to buy 200 million doses of a potential COVID-19 vaccine, the EU executive and the U.S. pharmaceutical company said on Thursday. The EU executive arm said this paved the way for contractual talks and the possible purchase of the vaccine on behalf of all 27 EU states once it has proven safe and effective. The commission also said it could purchase an additional 200 million vaccine doses. Johnson & Johnson, through its Belgian subsidiary Janssen, “will now enter into contract negotiations with the European Commission,” J&J said in a statement, confirming the volumes indicated by the Commission. “If regulatory approval for the company’s vaccine is received, the Commission would be expected to facilitate a process for allocation of the vaccine doses among the member states,” Johnson & Johnson said. J&J could produce up to 1 billion doses of its vaccine by the end of 2021, a company executive told Reuters on Tuesday.
— Novinite

Should you be investing money in pharma stocks?

Thursday, 13 August 2020, 18:43:06
The healthcare and pharmaceutical industry has been growing steadily for years. The UK in particular is home to pharma giants like GlaxoSmithKline and Astrazeneca, with market caps of over £80bn. But there are also some small caps that I think deserve attention when it comes to investing money in the sector. Allergy Therapeutics (LSE:AGY) is a […] The post Should you be investing money in pharma stocks? appeared first on The Motley Fool UK .
— The Motley Fool UK

GlaxoSmithKline : CureVac Sets IPO at 13.3 Million Shares; Sees Pricing at $14-$16 Each | MarketScreener

Monday, 10 August 2020, 18:11:02
By Colin Kellaher Germany’s CureVac B.V., which is working on a coronavirus vaccine, on Monday said it plans to sell about 13.3 million shares at between $14 and $16 each in its planned U.S…. | August 10, 2020
— MarketScreener

The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs

Friday, 7 August 2020, 13:34:07
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson’s disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Natera Inc (NASDAQ: NTRA ) PDL BioPharma Inc (NASDAQ: PDLI ) Sangamo Therapeutics Inc (NASDAQ: SGMO ) (reacted to its second-quarter results) Shockwave Medical Inc (NASDAQ: SWAV ) SurModics, Inc. (NASDAQ: SRDX )(reacted to its second-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Unity Biotechnology Inc (NASDAQ: UBX ) Zoetis Inc (NYSE: ZTS ) (reacted to its second-quarter results) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 6) Nkarta Inc (NASDAQ: NKTX ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX )(announced its second-quarter results) Stocks In Focus Zosano Clinches Distribution Deal For Investigational Migraine Patch Zosano Pharma Corp (NASDAQ: ZSAN ) said it has partnered with Eversana commercialize and distribute Qtrypta in the U.S.
— Benzinga

Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval

Thursday, 6 August 2020, 14:00:00
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline’s (GSK) BLENREP™ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. The approval triggers a $20 million milestone payment and entitles Seattle Genetics to royalties on BLENREP pr
— Business Wire